Artelon announced today that it closed a Series B funding round worth proceeds of approximately $20 million.
Marietta, Georgia–based Artelon plans to use proceeds to fund commercial growth and clinical research. It may also go toward expanding the company’s product line for the surgical treatment of ankles and other joints.
Artelon develops its proprietary Dynamic Matrix technology. The company designed the proprietary bio-textile for musculoskeletal soft tissue reconstruction.
Dynamic Matrix mimics the natural mechanical and biological properties of healing ligament tissue. Clinical studies demonstrated its ability to protect the surgical repair during early healing and quickly restore the mechanics of motion. It can also help support the development of regenerating tissue before dissolving over five to six years.
Vensana Capital led the funding round with expected additional participation from existing investors.
“Artelon has …